PPARG and early-onset autosomal dominant Alzheimer disease: IAA intake at 1 mg/kg for 7 days was shown to reduce microglial inflammation and improve neural hyperactivation, which was detected using manganese MRI in an Alzheimer's disease mouse model.4 In addition, IAAs have been reported to activate the peroxisome proliferator‐activated receptor (PPAR)‐γ.13 Low‐dose administration of the PPAR‐γ agonist pioglitazone improved resting‐state functional connectivity in rat brains.14 These reports suggest that the suppression of inflammation by IAAs through PPAR‐γ may be associated with GM‐BHQ improvement.